Moody's Affirms Ascension's Aa3 Rating, Flags Medicaid Funding Risk

Moody's Ratings affirmed Ascension's "Aa3" rating and stable outlook in an Oct. 1 report, citing the health system's leading market positions and scale efficiencies. The agency noted Ascension's $3.9 billion Amsurg acquisition, completed in June, should boost margins by expanding non-acute service lines, though leverage remains high with cash-to-adjusted-debt near 150-160%. Moody's flagged near-term pressure from rising uncompensated care tied to expiring enhanced ACA subsidies and declining Medicaid eligibility, plus added strain beginning in 2028 from Ascension's "heavy reliance" on Medicaid supplemental funding programs. Ascension narrowed its fiscal 2026 operating loss to $120 million from $491 million the prior year.

Finance